Annovis Bio Inc. (ANVS) |
|
13.04 -0.49 (-3.62%)
|
01-21 18:33 |
|
Open: |
13.43 |
Pre. Close: |
13.53 |
|
High:
|
13.66 |
Low:
|
12.96 |
|
Volume:
|
128,882 |
Market Cap:
|
106M |
|
|
|
|
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.68 - 13.776 |
13.776 - 13.849 |
|
Low:
|
12.717 - 12.843 |
12.843 - 12.94 |
|
Close:
|
12.866 - 13.036 |
13.036 - 13.167 |
|
Technical analysis |
as of: 2022-01-21 4:24:45 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 21.65  One year: 25.67 |
| Support: |
Support1: 12.96 Support2: 10.78 |
| Resistance: |
Resistance1: 18.53 Resistance2: 21.98 |
| Pivot: |
16.27 |
| Moving Average: |
MA(5): 14.10 MA(20): 16.98
MA(100): 26.16 MA(250): 38.54 |
| MACD: |
MACD(12,26): -2.12 Signal(9): -1.92 |
| Stochastic oscillator: |
%K(14,3): 1.65 %D(3): 4.19 |
| RSI: |
RSI(14): 27.26 |
| 52-week: |
High: 132.00 Low: 9.71 Change(%): 31.1 |
| Average Vol(K): |
3-Month: 164 10-Days: 97 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ANVS has closed above bottom band by 6.9%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 19 Jan 2022
Insiders might want to re-evaluate their US$658k stock purchase as Annovis Bio, Inc. (NYSE:ANVS) drops to US$117m - Nasdaq
Mon, 10 Jan 2022
Annovis Bio Enhances Leadership Team with Two Senior Appointments - Yahoo Finance
Wed, 05 Jan 2022
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 - The Kingston Whig-Standard
Mon, 03 Jan 2022
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - Yahoo Finance
Thu, 30 Dec 2021
What You Need To Know About Annovis Bio, Inc.'s (NYSE:ANVS) Investor Composition - Simply Wall St
Mon, 20 Dec 2021
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders - Yahoo Finance
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
8 |
| Shares Float (M) |
6 |
|
% Held by Insiders
|
31.05 |
|
% Held by Institutions
|
18.55 |
|
Shares Short (K)
|
394 |
|
Shares Short P. Month (K)
|
458 |
Stock Financials |
|
EPS
|
-1.400 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
5.740 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-23.1 |
|
Return on Equity (ttm)
|
-36.9 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-8 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
-9.31 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.27 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
